The stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) hit a new 52-week low and has $1.86 target or 14.00% below today’s $2.16 share price. The 9 months bearish chart indicates high risk for the $84.43 million company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $1.86 price target is reached, the company will be worth $11.82 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 103,922 shares traded hands. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has declined 39.72% since March 29, 2016 and is downtrending. It has underperformed by 43.20% the S&P500.
Analysts await Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to report earnings on November, 4. They expect $-0.35 earnings per share, down 20.69% or $0.06 from last year’s $-0.29 per share. After $-0.35 actual earnings per share reported by Anthera Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Ratings Coverage
Out of 4 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anthera Pharmaceuticals has been the topic of 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The rating was initiated by H.C. Wainwright on Friday, July 8 with “Buy”. Zacks upgraded Anthera Pharmaceuticals Inc (NASDAQ:ANTH) on Thursday, August 13 to “Hold” rating. Suntrust Robinson initiated Anthera Pharmaceuticals Inc (NASDAQ:ANTH) on Wednesday, September 9 with “Buy” rating. The company was initiated on Wednesday, September 9 by SunTrust. The rating was initiated by Citigroup with “Buy” on Thursday, September 17. The stock has “Buy” rating given by Jefferies on Friday, February 19.
According to Zacks Investment Research, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, SjÃ¶gren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.”
Insitutional Activity: The institutional sentiment increased to 1.7 in Q2 2016. Its up 0.76, from 0.94 in 2016Q1. The ratio is positive, as 6 funds sold all Anthera Pharmaceuticals Inc shares owned while 14 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 22.69 million shares or 1.80% less from 23.11 million shares in 2016Q1.
Tfs Limited Liability Com has 16,867 shares for 0.01% of their US portfolio. Alliancebernstein Ltd Partnership has 0% invested in the company for 25,500 shares. Millennium Lc holds 64,569 shares or 0% of its portfolio. California Public Employees Retirement System last reported 102,125 shares in the company. Moreover, Jacobs Levy Equity has 0.01% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 82,175 shares. Allianz Asset Management Ag accumulated 0% or 184,213 shares. Jefferies Lc, a New York-based fund reported 50,000 shares. Comml Bank Of America De holds 0% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 26,569 shares. Morgan Stanley owns 9,756 shares or 0% of their US portfolio. Moreover, Tiaa Cref Investment Ltd Com has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 212,457 shares. Weiss Multi last reported 60,143 shares in the company. Credit Suisse Ag, a Switzerland-based fund reported 23,397 shares. Citigroup last reported 0% of its portfolio in the stock. Hightower Advsrs Limited Co holds 50,100 shares or 0% of its portfolio. Vanguard Gru owns 1.48M shares or 0% of their US portfolio.
More notable recent Anthera Pharmaceuticals Inc (NASDAQ:ANTH) news were published by: Fool.com which released: “Why Anthera Pharmaceuticals, Inc. Shares Are Soaring Higher” on June 05, 2015, also Marketwatch.com with their article: “Anthera Pharma stock rises 7% on safety review board’s go-ahead for late-stage …” published on August 16, 2016, Thestreet.com published: “Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering” on July 09, 2015. More interesting news about Anthera Pharmaceuticals Inc (NASDAQ:ANTH) were released by: Seekingalpha.com and their article: “Anthera Pharmaceuticals: Buy Low Opportunity On Potential Drug Approval” published on February 02, 2016 as well as 247Wallst.com‘s news article titled: “Tuesday’s Top Health Care Movers” with publication date: August 16, 2016.
ANTH Company Profile
Anthera Pharmaceuticals, Inc. (Anthera), incorporated on October 9, 2004, is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.